Astrazeneca - Bio, News, Photos - Washington Times
Skip to content

Astrazeneca

Latest Stories

britain_earns_astrazeneca_15898.jpg

britain_earns_astrazeneca_15898.jpg

FILE - In this file photo dated Jan. 29, 2009, reflections are seen in the sign at the global headquarters of AstraZeneca in London. Shares in Anglo-Swedish drugmaker AstraZeneca plunged 16 percent on Thursday July 27, 2017, after a new lung cancer drug trial did not prove as successful as the company had hoped. (AP Photo/Kirsty Wigglesworth/FILE)

insider_q_and_a_astrazeneca_77677.jpg

insider_q_and_a_astrazeneca_77677.jpg

This undated photo provided by AstraZeneca on May 26, 2017 shows their CEO Guy Yeoman. Drugmakers, including AstraZeneca, are finding they can improve how drug testing is conducted_ and help their own bottom lines _ by giving patients a voice before testing even begins. (AstraZeneca via AP)

fda-bladder_cancer_drug_67379.jpg

fda-bladder_cancer_drug_67379.jpg

This image provided by AstraZeneca shows the company's drug Imfinzi, known chemically as durvalumab. On Monday, May 1, 2017, the Food and Drug Administration approved Imfinzi, part of the new generation of immuno-oncology drugs, which help the immune system to fight off cancer. The FDA also approved a companion diagnostic test for identifying which patients are most likely to benefit from the drug. (AstraZeneca via AP)

abce162792834714550f6a70670050b5.jpg

abce162792834714550f6a70670050b5.jpg

FILE - This July 24, 2013 file photo shows the AstraZeneca logo on the company's building in Shanghai, China. Pfizer says it does not intend to make a takeover offer for British drugmaker AstraZeneca. The Monday, May 26, 2014 announcement comes a week after AstraZeneca's board rejected a proposed $119 billion buyout offer from Pfizer, the world's second-biggest drugmaker by revenue. (AP Photo/Eugene Hoshiko, File)

0fe66e2392844714550f6a7067000c3c.jpg

0fe66e2392844714550f6a7067000c3c.jpg

In this May 4, 2014 photo, the Pfizer logo is displayed on the exterior of a former Pfizer factory in the Brooklyn borough of New York. Pfizer says it does not intend to make a takeover offer for British drugmaker AstraZeneca. The Monday, May 26, 2014 announcement comes a week after AstraZeneca's board rejected a proposed $119 billion buyout offer from Pfizer, the world's second-biggest drugmaker by revenue. (AP Photo/Mark Lennihan, File)

0059be4295059a13540f6a706700dcbc.jpg

0059be4295059a13540f6a706700dcbc.jpg

FILE - This Friday May 2, 2014 file photo shows an exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London. The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, Monday May 19, 2014, a decision that has caused a sharp slide in the U.K. company's share price as investors think it effectively brings an end to the protracted and increasingly bitter takeover saga. (AP Photo/Matt Dunham, File)

70d0100e30440211530f6a706700c8de.jpg

70d0100e30440211530f6a706700c8de.jpg

An exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London, Friday, May 2, 2014. The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion. (AP Photo/Matt Dunham)

3a29b80e30440211530f6a706700d0c6.jpg

3a29b80e30440211530f6a706700d0c6.jpg

An exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London, Friday, May 2, 2014. The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion. (AP Photo/Matt Dunham)